Clinical trial
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With…
NCT00322556 · CSL Behring, Industry · Completed
Key facts
| NCT number | NCT00322556 |
|---|---|
| Title | Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) |
| Official title | A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID) |
| Lead sponsor | CSL Behring, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency |
| Intervention type | Drug |
| Interventions | Immunoglobulins Intravenous (Human) |
| Enrollment | 55 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 8, 2006 |
| Last update posted | Oct 26, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: